{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:39Z","timestamp":1787014359035,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Patients with homologous recombination repair gene altered (\n                      <jats:italic>HRR<\/jats:italic>\n                      +) metastatic castration\u2010resistant prostate cancer (mCRPC) have a poor prognosis but achieved clinical benefits when treated with first\u2010line niraparib and abiraterone acetate plus prednisone (niraparib\u2009+\u2009AAP) in the MAGNITUDE trial. We report final exploratory results from MAGNITUDE for the subgroup of patients with Breast Cancer gene\u2010positive (\n                      <jats:italic>BRCA+<\/jats:italic>\n                      ) mCRPC enrolled in Asia (NCT03748641).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants with\n                      <jats:italic>HRR<\/jats:italic>\n                      \u2009+\u2009mCRPC were randomized 1:1 to treatment with niraparib + AAP or placebo + AAP. The primary endpoint of radiographic progression\u2010free survival (rPFS) by blinded independent central review (BICR) and secondary survival endpoints were calculated for the BRCA+ Asian subgroup. Safety was assessed in the Asian HRR+ population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Asian subgroup included 35 participants with\n                      <jats:italic>BRCA<\/jats:italic>\n                      \u2009+\u2009mCRPC (all\n                      <jats:italic>BRCA2<\/jats:italic>\n                      +). After 34.99\u2009months of follow\u2010up, median rPFS by BICR was 38.6\u2009months in the niraparib\u2009+\u2009AAP group versus 8.3\u2009months in the placebo+AAP group (hazard ratio [HR] 0.33, 95% confidence interval [CI] 0.13\u20130.83, nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2010value\u2009=\u20090.0141). Clinically relevant benefits were also observed in time to PSA progression (HR 0.32, 95% CI 0.13\u20130.83), and time to cytotoxic chemotherapy (HR 0.098, 95% CI 0.01\u20130.68). Median overall survival was not reached in the niraparib+AAP group and was 24.0\u2009months in the placebo+AAP group (HR 0.67, 95% CI 0.27\u20131.71). The safety profile of niraparib+AAP was consistent with the main study population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In this final exploratory analysis of the Asian subgroup, participants with\n                      <jats:italic>BRCA<\/jats:italic>\n                      \u2009+\u2009mCRPC continued to benefit from first\u2010line treatment with niraparib + AAP in comparison to placebo + AAP, with efficacy and toxicity profiles consistent with the global study population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      United States National Library of Medicine (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\">https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      ); NCT03748641\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70455","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:59:36Z","timestamp":1776844776000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Niraparib With Abiraterone Acetate Plus Prednisone as First\u2010Line Therapy in Patients With Metastatic Castration\u2010Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-2525","authenticated-orcid":false,"given":"Dingwei","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Urology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marniza","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine Universiti Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology Cancer Center, Seoul St. Mary's Hospital The Catholic University of Korea  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonho","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology Keimyung University Dongsan Hospital  Daegu South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See\u2010Tong","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Urology, Chang Gung Memorial Hospital Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-8722","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology The First Affiliated Hospital of Xi'an Jiaotong University  Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[{"name":"Macquarie University Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[{"name":"Research Department of Oncology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University of British Columbia, BC Cancer \u2010 Vancouver Center  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel","family":"Mundle","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anildeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine Peter MacCallum Cancer Center and the University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13593"},{"key":"e_1_2_12_3_1","unstructured":"World Health Organization. International Agency for Research on Cancer. Globoal Cancer Observatory \u201cGlobocan 2022. Asia \u201dhttps:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/935\u2010asia\u2010fact\u2010sheet.pdf."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312628"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00358"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103708"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16712"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.12.001"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.004"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad185"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032\u2010022\u201001648\u20105"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33324"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010022\u201001167\u20106"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.012"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:52:02Z","timestamp":1777027922000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/iju.70455"],"URL":"https:\/\/doi.org\/10.1111\/iju.70455","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70455"}}